Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (NYSE:GEHC) announced a commercial digital integration linking the bkActiv intraoperative ultrasound system with the Medtronic Stealth AXiS surgical navigation system to provide real-time imaging during cranial procedures.
The integration supports plug-and-play visualization to help assess anatomy changes such as brain shift and complements planning, navigation and robotics; the Stealth AXiS has U.S. FDA clearance for cranial procedures.
GE HealthCare (Nasdaq: GEHC) will release first quarter 2026 financial results before market open on Wednesday, April 29, 2026.
The GE HealthCare management team will host a live conference call and webcast at 8:30 a.m. ET the same day. Materials and a replay will be posted on the company investor website.
GE HealthCare (Nasdaq: GEHC) warns shareholders to reject an unsolicited mini-tender by Potemkin Limited offering up to 100,000 shares at $45.80 per share. The offer price is ~34.80% below the $70.25 closing price on March 18, 2026.
The company says the offer contains conditions, potential payment delays, and limited withdrawal rights, urges investors to obtain current market quotations, consult advisors, and take no action if they have not tendered.
GE HealthCare (Nasdaq: GEHC) will serve as the industry lead in COMPASS, a five-year, EU-funded IHI consortium with a total budget of €50.5 million and more than 60 partners to advance early detection and prediction of cardiotoxicity in cancer patients across Europe. The grant agreement was signed on March 25, 2026.
COMPASS will combine AI, advanced imaging, biomarkers and integrated care pathways to develop predictive tools, multi-omics biomarkers and an AI-powered clinical decision support pathway aimed at earlier diagnosis and coordinated cardio-oncology care.
GE HealthCare (Nasdaq: GEHC) will showcase cardiology innovations at ACC.26, including the newly U.S. FDA 510(k) cleared Photonova Spectra photon‑counting CT, ReadyFix fleet management for MAC VU360 ECG workstations, a U.S. collaboration with Gentuity, and recent Allia Moveo regulatory clearances.
Highlights emphasize ultra‑high‑definition imaging, AI‑enabled workflows, intravascular visualization, and operational tools intended to improve diagnostic confidence and device uptime across the cardiac care pathway.
GE HealthCare (Nasdaq: GEHC) received U.S. FDA 510(k) clearance for Photonova Spectra, a photon-counting CT system featuring Deep Silicon detectors with 8-bin energy resolution, 0.23s rotation speed, NVIDIA-accelerated reconstruction and a one-scan universal workflow. GE expects its innovation investments to support 1–2% revenue growth.
GE HealthCare (NYSE:GEHC) completed the acquisition of Intelerad for a base purchase price of $2.3 billion in cash, creating a cloud-first, AI-enabled enterprise imaging platform across ambulatory, teleradiology, and hospital settings. Intelerad’s first-year revenue is estimated at $270 million with ~90% recurring revenue and Adjusted EBITDA margin >30%. GE HealthCare expects immediate accretion to top-line growth and EBIT margin, slight short-term dilution to Adjusted EPS inclusive of financing costs, and a high-single-digit ROIC by year five.
GE HealthCare (Nasdaq: GEHC) appointed Kevin A. Lobo, Chair and CEO of Stryker (NYSE: SYK), to its Board of Directors effective March 13, 2026.
Mr. Lobo brings more than 25 years of medtech, operational and financial leadership, including service as Stryker CEO since October 2012 and Stryker board chair since July 2014, and experience at Johnson & Johnson, KPMG, Unilever and Kraft Canada.
GE HealthCare (NYSE:GEHC) announced on March 9, 2026 that View, the diagnostic viewer in the Genesis Radiology Workspace, received U.S. FDA 510(k) clearance. View is a cloud‑native, zero‑footprint diagnostic viewer offering high‑performance 2D/3D visualization, AI‑enabled tools, and direct access to Advanced Visualization in a single workflow.
The product aims to reduce radiologist non‑interpretive time (studies cite up to 44%) and enable remote, secure diagnostic access; availability varies by region.
GE HealthCare (Nasdaq: GEHC) will showcase AI, cloud-first and software solutions at HIMSS Global Health Conference & Exhibition 2026 in Las Vegas, March 9-12, 2026. The company will highlight CareIntellect for Perinatal, Command Center, Genesis Radiology Workspace, Imaging 360, Verisound ultrasound solutions, ViewPoint, and Vscan Air enterprise tools.
GE HealthCare emphasizes AI-enabled clinical workflows, device data interoperability through HL7 Caliper FHIR Accelerator membership, and demonstrations on reducing operational complexity for clinicians.